Sugi Predict

Sugi Predict / Compounds / SCHEMBL16774

SCHEMBL16774

SCHEMBL16774

CC(C)(C)OC(=O)N[C@@H](CC1CCOCC1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 5/20 0.57
▸ CTSK P43235 5/20 0.57
▸ IDO1 P14902 1/20 0.45
▸ AAK1 Q2M2I8 2/20 0.44
▸ KMT2A Q03164 2/20 0.41
▸ PPARA Q07869 5/20 0.40
▸ PPARG P37231 4/20 0.40
▸ ACE P12821 1/20 0.39
▸ CTSL P07711 1/20 0.39
▸ CTSB P07858 1/20 0.39
▸ PPARD Q03181 2/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16773 1.00 CTSS (0.57) CTSSCTSKIDO1AAK1KMT2A
SCHEMBL16119327 0.92 CTSS (0.52) CTSSCTSKIDO1AAK1KMT2A
SCHEMBL26120706 0.92 CTSS (0.52) CTSSCTSKIDO1AAK1KMT2A
SCHEMBL956167 0.90 CTSS (0.68) CTSSCTSKIDO1AAK1KMT2A
SCHEMBL956164 0.90 CTSS (0.68) CTSSCTSKIDO1AAK1KMT2A
SCHEMBL1351322 0.90 CTSS (0.68) CTSSCTSKIDO1AAK1KMT2A
SCHEMBL2199576 0.88 CTSK (0.53) CTSSCTSKAAK1KMT2ACTSL
SCHEMBL2199572 0.88 CTSK (0.53) CTSSCTSKAAK1KMT2ACTSL
SCHEMBL16800 0.88 CTSK (0.53) CTSSCTSKAAK1KMT2ACTSL
SCHEMBL24298421 0.87 CTSK (0.64) CTSSCTSKIDO1AAK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720058-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF Casma Therapeutics, Inc. (US) 2026-04-08 — — EP disclosed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
US-20250162989-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2025-05-22 — — US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
WO-2024249291-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF CASMA THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
CN-117836270-A USP30 inhibitors and uses thereof 文森雷生物科学股份有限公司 2024-04-05 — — CN disclosed
EP-4305021-A1 USP30 INHIBITORS AND USES THEREOF Vincere Biosciences, Inc. (US) 2024-01-17 — — EP disclosed
WO-2022192562-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. (US) 2022-09-15 — — WO disclosed
WO-2020131282-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS CORP. (MC) 2020-06-25 — — WO disclosed
US-10202353-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2019-02-12 — — US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 — — US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 — — US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 — — US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 — — US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 — — WO disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 — — WO disclosed
US-7115609-B2 Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases ELI LILLY AND COMPANY (US) 2006-10-03 — — US disclosed
US-20040254374-A1 Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases ELI LILLY AND COMPANY 2004-12-16 — — US disclosed
EP-1456198-A1 ALANYL-PIPERIDINE HETEROCYCLIC DERIVATIVES USEFUL AGAINST CARDIOVASCULAR DISEASES ELI LILLY AND COMPANY (US) 2004-09-15 — — EP disclosed
WO-2003050109-A1 ALANYL-PIPERIDINE HETEROCYCLIC DERIVATIVES USEFUL AGAINST CARDIOVASCULAR DISEASES ELI LILLY AND COMPANY (US) 2003-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 CTSS 4022/4885CTSK 4661/4885IDO1 2233/4885
US-20040254374-A1 Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases XPNPEP1, XDH, SERPINC1 CTSS 3515/4885CTSK 3274/4885IDO1 566/4885
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 CTSS 3395/4885CTSK 990/4885IDO1 4508/4885
US-10202353-B2 Therapeutic compounds RPL35, SARS1, HAVCR2 CTSS 436/4885CTSK 782/4885IDO1 3831/4885
US-20250162989-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 CTSS 2213/4885CTSK 2165/4885IDO1 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.